Rare germline large rearrangements in the BRCA1/2 genes and eight candidate genes in 472 patients with breast cancer predisposition

Breast Cancer Research and Treatment

Volumn 133, Issue 3, 2012, Pages 1179-1190

  Rouleau, E ^a   Jesson, B ^b   Briaux, A ^a   Nogues, C ^a   Chabaud, V ^b   Demange, L ^a   Sokolowska, J ^c   Coulet, F ^d   Barouk Simonet, E ^e   Bignon, Y J ^f   Bonnet, F ^e   Bourdon, V ^g   Bronner, M ^c   Caputo, S ^a   Castera, L ^h   Delnatte, C ⁱ   Delvincourt, C ^j   Fournier, J ^k   Hardouin, A ^l   Muller, D ^m   Peyrat, J P ^k   Toulas, C ⁿ   Uhrhammer, N ^f   Vidal, V ^b   Stoppa Lyonnet, D ^h   Bieche, I ^a   Lidereau, R ^a   more..

^a INSTITUT CURIE   (France)

^b IMAXIO Biopôle Clermont Limagne ^*  (France)

^c CHU NANCY BRABOIS   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e INSTITUT BERGONIÉ   (France)

^f CENTRE JEAN PERRIN   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j INSTITUT JEAN GODINOT   (France)

^k CENTRE OSCAR LAMBRET   (France)

^l CENTRE FRANÇOIS BACLESSE   (France)

^m CENTRE PAUL STRAUSS   (France)

ⁿ CANCER RESEARCH CENTER OF TOULOUSE   (France)

more..

Author keywords

BRCA1; BRCA2; Breast cancer predisposition; CGH array; Deletion; Duplication; Large rearrangements

Indexed keywords

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; ARTICLE; ATM GENE; BARD1 GENE; BREAST CANCER; BRIP1 GENE; CANCER PATIENT; CANCER SUSCEPTIBILITY; CHEK2 GENE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA FLANKING REGION; EXPLORATORY RESEARCH; FAMILIAL CANCER; FEMALE; FRAMESHIFT MUTATION; FRANCE; GENE; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC CODE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENOMICS; GERM LINE; HETEROZYGOTE; HUMAN; INCIDENCE; INTRON; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PALB2 GENE; PRIORITY JOURNAL; RAD50 GENE; RAD51 GENE; RAP80 GENE; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; PEDIGREE; YOUNG ADULT;

EID: 84863718085     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2009-5     Document Type: Article

References (52)

1. Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48(2):232-242
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kalli-oniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117-1130. doi:10.1086/375033
3. Chan KY, Liu W, Long JR, Yip SP, Chan SY, Shu XO, Chua DT, Cheung AN, Ching JC, Cai H, Au GK, Chan M, Foo W, Ngan HY, Gao YT, Ngan ES, Garcia-Barcelo MM, Zheng W, Khoo US (2009) Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women. J Med Genet 46(1):32-39. doi: 10.1136/jmg.2007.057174
4. 0 UTR of the BRCA1 gene in familial breast and/or ovarian cancer. Breast Cancer Res Treat 125(3):885-891. doi:10.1007/s10549-010-1165-8
5. Whiley PJ, Guidugli L, Walker LC, Healey S, Thompson BA, Lakhani SR, Da Silva LM, Tavtigian SV, Goldgar DE, Brown MA, Couch FJ, Spurdle AB (2011) Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. Hum Mutat 32(6):678-687. doi:10.1002/humu.21495
6. Sluiter MD, van Rensburg EJ (2011) Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat 125(2):325-349. doi:10.1007/s10549-010-0817-z
7. Mazoyer S (2005) Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat 25(5):415-422
8. Coulet F, Pires F, Rouleau E, Lefol C, Martin S, Colas C, Cohen-Haguenauer O, Giurgea I, Fajac A, Nogues C, Demange L, Hardouin A, Lidereau R, Soubrier F (2010) A one-step presc-reening for point mutations and large rearrangement in BRCA1 and BRCA2 genes using quantitative polymerase chain reaction and high-resolution melting curve analysis. Genet Test Mol Biomark 14(5):677-690. doi:10.1089/gtmb.2009.0183
9. Lim YK, Lau PT, Ali AB, Lee SC, Wong JE, Putti TC, Sng JH (2007) Identification ofnovel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer. Clin Genet 71(4):331-342. doi:10.1111/j.1399-0004.2007.00773.x
10. Agata S, Dalla Palma M, Callegaro M, Scaini MC, Menin C, Ghiotto C, Nicoletto O, Zavagno G, Chieco-Bianchi L, D'Andrea E, Montagna M (2005) Large genomic deletions inactivate the BRCA2 gene in breast cancer families. J Med Genet 42(10):e64
11. Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, Nord AS, Mandell JB, Swisher EM, King MC (2010) Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 107(28):12629-12633. doi:10.1073/pnas. 1007983107
12. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, Swisher EM (2011) Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108(44):18032-18037. doi: 10.1073/pnas.1115052108
13. Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11(2):103-105
14. Zhang B, Beeghly-Fadiel A, Long J, Zheng W (2011) Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 12(5):477-488. doi:10.1016/S1470-2045(11) 70076-6
15. CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10, 860 breast cancer cases and 9, 065 controls from 10 studies. Am J Hum Genet 74(6):1175-1182
16. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12):1379-1388
17. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38(8):873-875
18. Tommiska J, Seal S, Renwick A, Barfoot R, Baskcomb L, Jay-atilake H, Bartkova J, Tallila J, Kaare M, Tamminen A, Heikkila P, Evans DG, Eccles D, Aittomaki K, Blomqvist C, Bartek J, Stratton MR, Nevanlinna H, Rahman N (2006) Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer 118(11):2911-2916
19. Jakubowska A, Gronwald J, Menkiszak J, Gorski B, Huzarski T, Byrski T, Edler L, Lubinski J, Scott RJ, Hamann U (2007) The RAD51 135 G[C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. Cancer Epidemiol Biomark Prev 16(2):270-275
20. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Na-thanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Gorski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H, Spurdle AB, Chen X, Waddell N, Cloonan N, Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G (2007) RAD51 135G?C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 81(6):1186-1200
21. Kato M, Yano K, Matsuo F, Saito H, Katagiri T, Kurumizaka H, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Nagawa H, Nakamura Y, Miki Y (2000) Identification of Rad51 alteration in patients with bilateral breast cancer. J Hum Genet 45(3):133-137. doi:10.1007/s100380050199
22. De Nicolo A, Tancredi M, Lombardi G, Flemma CC, Barbuti S, Di Cristofano C, Sobhian B, Bevilacqua G, Drapkin R, Caligo MA (2008) A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res 14(14):4672-4680. doi:10.1158/1078-0432. CCR-08-0087
23. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165-167
24. Stacey SN, Sulem P, Johannsson OT, Helgason A, Gudmundsson J, Kostic JP, Kristjansson K, Jonsdottir T, Sigurdsson H, Hrafn-kelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Bergthorsson JT, Amundadottir LT, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K (2006) The BARD1 Cys557Ser variant and breast cancer risk in Iceland. PLoS Med 3(7):e217. doi: 10.1371/journal. pmed.0030217
25. De Brakeleer S, De Greve J, Loris R, Janin N, Lissens W, Ser-mijn E, Teugels E (2010) Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. Hum Mutat 31(3):E1175-E1185. doi: 10.1002/humu.21200
26. Akbari MR, Ghadirian P, Robidoux A, Foumani M, Sun Y, Royer R, Zandvakili I, Lynch H, Narod SA (2009) Germline RAP80 mutations and susceptibility to breast cancer. Breast Cancer Res Treat 113(2):377-381. doi:10.1007/s10549-008- 9938-z
27. Nikkila J, Coleman KA, Morrissey D, Pylkas K, Erkko H, Messick TE, Karppinen SM, Amelina A, Winqvist R, Greenberg RA (2009) Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function. Oncogene 28(16):1843-1852. doi:10.1038/onc.2009.33
28. Ferla R, Calo V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A (2007) Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18(Suppl 6):vi93-vi98. doi:10.1093/annonc/mdm234
29. Sabatier R, Adelaide J, Finetti P, Ferrari A, Huiart L, Sobol H, Chaffanet M, Birnbaum D, Bertucci F (2010) BARD1 homozy-gous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. Genes Chromosomes Cancer 49(12):1143-1151. doi:10.1002/gcc.20822
30. Cavalieri S, Funaro A, Pappi P, Migone N, Gatti RA, Brusco A (2008) Large genomic mutations within the ATM gene detected by MLPA, including a duplication of 41 kb from exon 4 to 20. Ann Hum Genet 72(Pt 1):10-18. doi:10.1111/j.1469- 1809. 2007.00399.x
31. Cavalieri S, Funaro A, Porcedda P, Turinetto V, Migone N, Gatti RA, Brusco A (2006) ATM mutations in Italian families with ataxia telangiectasia include two distinct large genomic deletions. Hum Mutat 27(10):1061. doi:10.1002/humu.9454
32. Blanco A, de la Hoya M, Balmana J, Ramon YCT, Teule A, Miramar MD, Esteban E, Infante M, Benitez J, Torres A, Tejada MI, Brunet J, Grana B, Balbin M, Perez-Segura P, Osorio A, Velasco EA, Chirivella I, Calvo MT, Feliubadalo L, Lasa A, Diez O, Carracedo A, Caldes T, Vega A (2011) Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-011-1842-2
33. Rouleau E, Lefol C, Tozlu S, Andrieu C, Guy C, Copigny F, Nogues C, Bieche I, Lidereau R (2007) High-resolution oligo-nucleotide array-CGH applied to the detection and characterization of large rearrangements in the hereditary breast cancer gene BRCA1. Clin Genet 72(3):199-207
34. Staaf J, Torngren T, Rambech E, Johansson U, Persson C, Sell-berg G, Tellhed L, Nilbert M, Borg A (2008) Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2, and MLH1 using zoom-in array comparative genomic hybridization (aCGH). Hum Mutat 29(4):555-564
35. Caux-Moncoutier V, Pages-Berhouet S, Michaux D, Asselain B, Castera L, De Pauw A, Buecher B, Gauthier-Villars M, Stoppa-Lyonnet D, Houdayer C (2009) Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study. Eur J Hum Genet 17(11):1471-1480
36. Barrois M, Bieche I, Mazoyer S, Champeme MH, Bressac-de Paillerets B, Lidereau R (2004) Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families. Clin Genet 65(2):131-136
37. Rouleau E, Lefol C, Moncoutier V, Castera L, Houdayer C, Caputo S, Bieche I, Buisson M, Mazoyer S, Stoppa-Lyonnet D, Nogues C, Lidereau R (2010) A missense variant within BRCA1 exon 23 causing exon skipping. Cancer Genet Cytogenet 202(2):144-146. doi:10.1016/j.cancergencyto.2010.07.122
38. Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL (2011) Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res 13(1):R20. doi:10.1186/bcr2832
39. Matsuzaki H, Wang PH, Hu J, Rava R, Fu GK (2009) High resolution discovery and confirmation of copy number variants in 90 Yoruba Nigerians. Genome Biol 10(11):R125. doi:10.1186/gb-2009-10-11-r125
40. Desrichard A, Bidet Y, Uhrhammer N, Bignon YJ (2011) CHEK2 germline mutation contribution to hereditary breast cancer in non-BRCA-mutated families. Breast Cancer Res 13(6):R119. doi: 10.1186/bcr3062
41. Tuohy TM, Done MW, Lewandowski MS, Shires PM, Saraiya DS, Huang SC, Neklason DW, Burt RW (2010) Large intron 14 rearrangement in APC results in splice defect and attenuated FAP. Hum Genet 127(3):359-369. doi:10.1007/s00439- 009-0776-9
42. Li L, Cohen M, Wu J, Sow MH, Nikolic B, Bischof P, Irminger-Finger I (2007) Identification of BARD1 splice-isoforms involved in human trophoblast invasion. Int J Biochem Cell Biol 39(9):1659-1672. doi:10.1016/j.biocel.2007.04. 018
43. Li L, Ryser S, Dizin E, Pils D, Krainer M, Jefford CE, Bertoni F, Zeillinger R, Irminger-Finger I (2007) Oncogenic BARD1 iso-forms expressed in gynecological cancers. Cancer Res 67(24):11876-11885. doi:10.1158/0008-5472.CAN- 07-2370
44. Ryser S, Dizin E, Jefford CE, Delaval B, Gagos S, Christodou-lidou A, Krause KH, Birnbaum D, Irminger-Finger I (2009) Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2. Cancer Res 69(3):1125-1134. doi:10.1158/0008-5472.CAN-08-2134
45. Tsuzuki M, Wu W, Nishikawa H, Hayami R, Oyake D, Yabuki Y, Fukuda M, Ohta T (2006) A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats. Cancer Lett 233(1):108-116. doi:10.1016/j.canlet.2005.03. 012
46. Brown MA, Lo LJ, Catteau A, Xu CF, Lindeman GJ, Hodgson S, Solomon E (2002) Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: identification of a novel deletion consistent with BRCA1:psiBRCA1 recombination. Hum Mutat 19(4):435-442. doi:10.1002/humu.10055
47. Benko S, Fantes JA, Amiel J, Kleinjan DJ, Thomas S, Ramsay J, Jamshidi N, Essafi A, Heaney S, Gordon CT, McBride D, Golzio C, Fisher M, Perry P, Abadie V, Ayuso C, Holder-Espinasse M, Kilpatrick N, Lees MM, Picard A, Temple IK, Thomas P, Vazquez MP, Vekemans M, Roest Crollius H, Hastie ND, Munnich A, Etchevers HC, Pelet A, Farlie PG, Fitzpatrick DR, Lyonnet S (2009) Highly conserved non-coding elements on either side of SOX9 associated with Pierre Robin sequence. Nat Genet 41(3):359-364. doi:10.1038/ng.329
48. Dowty JG, Lose F, Jenkins MA, Chang JH, Chen X, Beesley J, Dite GS, Southey MC, Byrnes GB, Tesoriero A, Giles GG, Hopper JL, Spurdle AB (2008) The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian women. Breast Cancer Res Treat 112(1):35-39. doi:10.1007/s10549-007-9832-0
49. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Eccles D, Evans DG, Renwick A, Seal S, Lord CJ, Ashworth A, Reis-Filho JS, Antoniou AC, Rahman N (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43(9):879-882. doi:10.1038/ng.893ng.893
50. Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, Bowden NA, Scott RJ (2011) BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat 127(3):853-859. doi: 10.1007/s10549-011-1443-0
51. Romero A, Perez-Segura P, Tosar A, Garcia-Saenz JA, Diaz-Rubio E, Caldes T, de la Hoya M (2011) A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families. Breast Cancer Res Treat. doi:10.1007/s10549-011-1543-x
52. Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI (2010) Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat 124(3):857-861. doi:10.1007/s10549-010- 1095-5